These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19075685)

  • 41. Innovative and economic potential of mammalian cell culture.
    Werner RG
    Arzneimittelforschung; 1998 Apr; 48(4):423-6. PubMed ID: 9608886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The drug discovery and development process in the new millennium.
    Levy MD
    Can J Gastroenterol; 2000; 14(7):641-3. PubMed ID: 10978952
    [No Abstract]   [Full Text] [Related]  

  • 43. Next-generation monoclonals less profitable than trailblazers?
    Mitchell P
    Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
    [No Abstract]   [Full Text] [Related]  

  • 44. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Production of monoclonal antibodies in plants for cancer immunotherapy.
    Moussavou G; Ko K; Lee JH; Choo YK
    Biomed Res Int; 2015; 2015():306164. PubMed ID: 26550566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The power of genomics to transform the biotechnology industry.
    Haseltine WA
    Nat Biotechnol; 1998 May; 16 Suppl():25-7. PubMed ID: 9591259
    [No Abstract]   [Full Text] [Related]  

  • 47. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing the impact of genomics on drug discovery and development.
    Crooke ST
    Nat Biotechnol; 1998 May; 16 Suppl():29-30. PubMed ID: 9591260
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic peptides: technological advances driving peptides into development.
    Sato AK; Viswanathan M; Kent RB; Wood CR
    Curr Opin Biotechnol; 2006 Dec; 17(6):638-42. PubMed ID: 17049837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.
    Li J; Sai T; Berger M; Chao Q; Davidson D; Deshmukh G; Drozdowski B; Ebel W; Harley S; Henry M; Jacob S; Kline B; Lazo E; Rotella F; Routhier E; Rudolph K; Sage J; Simon P; Yao J; Zhou Y; Kavuru M; Bonfield T; Thomassen MJ; Sass PM; Nicolaides NC; Grasso L
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3557-62. PubMed ID: 16505368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmaceutical industry in the Arab world: challenges, controversies, and future outlook.
    Kandil O
    Drug Discov Today; 2004 Jul; 9(13):543-5. PubMed ID: 15203084
    [No Abstract]   [Full Text] [Related]  

  • 52. Bristol-Myers Squibb locks into novel autoimmune strategy.
    Garber K
    Nat Biotechnol; 2016 Jun; 34(6):577-9. PubMed ID: 27281396
    [No Abstract]   [Full Text] [Related]  

  • 53. MipTec: breaking down the silos of information.
    Yates I
    Drug Discov Today; 2004 Oct; 9(20):871-3. PubMed ID: 15475319
    [No Abstract]   [Full Text] [Related]  

  • 54. Optimism after much pessimism: what next?
    Milstein C; Waldmann H
    Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
    [No Abstract]   [Full Text] [Related]  

  • 55. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug Delivery 2007--New technologies, partnering and strategies for the future.
    Stevenson L
    IDrugs; 2007 Jun; 10(6):388-90. PubMed ID: 17642001
    [No Abstract]   [Full Text] [Related]  

  • 57. [Biomanufacturing of monoclonal antibodies].
    Joubert S; Dodelet V; Béliard R; Durocher Y
    Med Sci (Paris); 2019 Dec; 35(12):1153-1159. PubMed ID: 31903930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective.
    Narasimhan C; Mach H; Shameem M
    Ther Deliv; 2012 Jul; 3(7):889-900. PubMed ID: 22900469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What's next for an immuno-oncology powerhouse?
    Mullard A
    Nat Rev Drug Discov; 2021 Sep; 20(9):660-661. PubMed ID: 34389830
    [No Abstract]   [Full Text] [Related]  

  • 60. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.